A multicenter, prospective, simultaneous controlled and exploratory clinical study on the treatment of new dignosed Diff typinguse large B-cell Lymphoma with RCHOP regimen and X drugs under the guidance of Next Generation Sequencing

A multicenter, prospective, simultaneous controlled and exploratory clinical study on the treatment of new dignosed Diff typinguse large B-cell Lymphoma with RCHOP regimen and X drugs under the guidance of Next Generation Sequencing - Hematological

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068820

Enrollment

Unknown

Registered

2023-03-01

Start date

2023-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell Lymphoma

Interventions

Research group:RCHOP+X

Control group:RCHOP

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Diffuse large B-cell lymphoma with positive CD20 was confirmed by histopathology. 2) There is at least one imageable lesion. 3) The IPI score is 2-5 points, the age at the time of enrollment is 18-65 years old, and the ECOG score is 0-2 points. 4) Obtain informed consent signed by the patient or family member.

Exclusion criteria

Exclusion criteria: 1) Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures. 2) Abnormal liver function (total bilirubin>1.5 times of the upper normal limit, ALT/AST>2.5 times of the upper normal limit or ALT/AST>5 times of the upper normal limit in patients with liver invasion), abnormal renal function (serum creatinine>1.5 times of the upper normal limit). 3) Neutrophil absolute count1x105 copies/ml), untreated syphilis positive persons and active tuberculosis patients. 9) Previous lymphoma history, considering Richter's transformation. 10) Other researchers judged that it was not suitable for this study.

Design outcomes

Primary

Measure	Time frame
Overall response rate;	—

Secondary

Measure	Time frame
Complete response rate;progression-free survival(PFS);Overall Survival rate(OS);safety;	—

Countries

China

Contacts

Public ContactTonghongyan

The First Affiliated Hospital of Zhejiang University Medical College

hongyantong@aliyun.com13958122357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026